pharma · Nasopharyngeal Carcinoma · Safety of Almonertinib
Sun Yat-sen University
Sun Yat-sen University clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 广州市新港西路135号, CN
- Employees
- 3,680
- Programs
- 19
- Drugs
- 25
- Patents
- 0
Sun Yat-sen University projects
5 ClinicalTrials.gov programs sponsored by Sun Yat-sen University.
Sun Yat-sen University has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Chemotherapy
Sun Yat-sen University
Nasopharyngeal Carcinoma
1 trial -
Cytokine-Induced Killer Cells
Sun Yat-sen University
Carcinoma, Hepatocellular
1 trial -
Palliative Chemotherapy
Sun Yat-sen University
Colorectal Neoplasms Malignant
1 trial -
gemcitabine and cisplatin (Induction chemotherapy)
Sun Yat-sen University
Nasopharyngeal Carcinoma
1 trial -
postoperative antimicrobial prophylaxis
Sun Yat-sen University
Hepatocellular Carcinoma
1 trial
Frequently asked questions
How many clinical projects does Sun Yat-sen University have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.